Meropenem/vaborbactam - Melinta Therapeutics

Drug Profile

Meropenem/vaborbactam - Melinta Therapeutics

Alternative Names: Carbavance™; Meropenem and vaborbactam; Meropenem/RPX-7009; RPX-2014/RPX-7009; RPX-7009/RPX-2014; Vabomere

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rempex Pharmaceuticals
  • Developer Melinta Therapeutics; US Department of Health and Human Services
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urinary tract infections
  • Phase III Bacteraemia; Gram-negative infections; Pneumonia; Pyelonephritis

Most Recent Events

  • 23 Apr 2018 Additional safety and efficacy data from the phase III TANGO 2 trial presented at the Annual Meeting of the the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 21 Apr 2018 Pharmacokinetics data from an ex vivo study presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 08 Jan 2018 Melinta Therapeutics acquires Meropenem/Vaborbactam from The Medicines Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top